AnGes Takes Gene Editor Emendo Into Fold For $258m
Attractive Allele-Specific Platform
Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.
Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.